Primary hemophagocytic lymphohistiocytosis in adults: the utility of family surveys in a single-center study from China

Zhili Jin, Yini Wang, Jingshi Wang, Jia Zhang, Lin Wu, Zhuo Gao, Wenyuan Lai and Zhao Wang*

Abstract

Background: This study investigated the clinical characteristics of primary hemophagocytic lymphohistiocytosis (HLH) in adults, including immunological markers, pedigree findings, and conditions of allogeneic hematopoietic stem cell transplantation (Allo-HSCT).

Methods: The study included clinical data of 18 adult patients with primary HLH treated in our center from June 2010 to January 2017.

Results: Of these 18 cases, pathogenic variants were found in the following genes: PRF1 (n = 11), UNC13D (n = 5), SH2D1A (n = 2), RAB27a (n = 1), and LYST (n = 2). One patient had pathogenic variants in both PRF1 and UNC13D genes, one patient had pathogenic variants in both LYST and UNC13D genes and another patient had pathogenic variants in both PRF1 and SH2D1A genes. Additionally, 3 of the 18 cases involved homozygous pathogenic variants, while 2 cases involved hemizygous pathogenic variants. The remaining 13 cases involved compound heterozygous pathogenic variants. The natural killer (NK) cell activity test was conducted in all 18 cases where 14(77.8%) patients showed reduction in NK cell activity. Furthermore, this article presents 3 representative results of the pedigree findings from 12 patients who underwent family surveys. The 8 patients who underwent Allo-HSCT had a median survival of 27.2 months, as compared with the median survival of 7 months for the10 patients who did not undergo Allo-HSCT, a significant difference between the two groups of patients (p = 0.006).

Conclusion: PRF1 was one of the most commonly mutated gene in adult patients with primary HLH. Family surveys and immunological markers were important for the HLH diagnosis and the selection of an appropriate donor. Allo-HSCT was an effective therapy for adult primary HLH.

Keywords: Primary hemophagocytic lymphohistiocytosis in adults, Family surveys, Immunological markers, Allogeneic hematopoietic stem cell transplantation

Background

Primary HLH is an autosomal and/or X-linked recessive inheritance characterized by immune disorders. In the past, diagnosis of patients with primary HLH was based on a disease onset at an early age and a positive family history. In 1999, a research group in Paris reported the first primary HLH-related gene map [1]. The “HLH-2004: diagnostic criteria for hemophagocytic lymphohistiocytosis” proposed by the Histiocyte Society clearly reported that genetic defects are the gold standard of primary HLH. At least 12 relevant genes associated with primary HLH have been reported, include: PRF1, UNC13D, STX11, STXBP2, SH2D1A, BIRC4, RAB27A, LYST, ADTB3A, ITK, CD27 and MAGT1 [2]. With the gradual understanding of adult primary HLH, age is no longer the basis for the diagnosis. Currently, delayed onset of adult primary HLH has been considered to relate to the gene pathogenic variants, the pathogenic variant patterns, and the presence of a trigger.
Immunological markers are important for the early diagnosis of primary HLH. Janka et al. [3] showed that NK cell activity was reduced in almost all patients at the early stage of primary HLH. Thus, timely detection of NK cell activity is important for the early diagnosis of the disease. CD107a detection can be used as a highly sensitive method for the identification of primary HLH [4]. Timely detection of the immunological markers has been considered to be significantly better than genetic testing and has been used as an effective and rapid screening for primary HLH in the diagnostic processes of international studies [4, 5].

Early diagnosis of primary HLH may require a positive family history gained from family surveys of individuals with abnormal immunological markers or suspected primary HLH as a supportive basis to help confirm the diagnosis. Carrier testing of family members through gene sequencing, cytotoxicity analysis and protein measurements can result not only in the identification of yet healthy homozygous carriers but also aid the selection of suitable donors in the family.

The long-term strategy of HLH treatment is to correct the immunodeficiency, so patients with primary HLH require Allo-HSCT to correct the potential genetic defects. Allo-HSCT is recommended by HLH-94 for FHL and refractory recurrent HLH patients, using the traditional myeloablative pretreatment regimen [6]. Combined chemotherapy only temporarily controls the incidence of FHL effectively. Patients who do not receive Allo-HSCT cannot achieve long-term survival [7]. Henter et al. [8] reported the first multicenter prospective study in 2002 and showed that remission occurred in 119 primary HLH patients after combined chemotherapy and subsequent HSCT. Clear recovery was observed with an overall survival rate of 55% in the 43-year follow up where the majority of deaths occurred after the early diagnosis or before the transplantation. More and more clinical studies have shown that Allo-HSCT is the only curative regimen for adult primary HLH. Currently, publications regarding adult primary HLH diagnosis and treatment are few and most of them are case reports. We conducted a related study to identify the clinical characteristics in the adult patients with primary HLH.

Methods
Research subject
Eighteen adult patients with primary HLH, diagnosed and treated in Beijing Friendship Hospital, Capital Medical University from June 2010 to January 2017, were included in this study. All patients (≥ 18 years old) underwent genetic testing and were found to have primary HLH-related genetic defects. (Supplement: Zhang K et al. considered that “In patients with combination defects involving 2 genes in the degranulation pathway, CD107a degranulation was decreased, comparable to patients with biallelic mutations in one of the genes in the degranulation pathway. This suggests a potential digenic mode of inheritance of FHL as a result of a synergistic function effect within genes involved in cytotoxic lymphocyte degranulation.” [9] and Sepulveda et al. considered that an additive effect of HLH mutations in different genes has been shown in mouse models [10]. So the patient who has defects involving 2 genes in the degranulation pathway and CD107a degranulation decreased (P14) and the patient who has polygenic inheritance additive effect(P15) were diagnosed with presumably primary HLH in our center.

Immunological markers and family surveys of adult HLH patients
Immunological markers of the 18 adult patients with primary HLH were assessed using a cytotoxicity assay, CD107a degranulation assay, perforin, granzyme, signaling lymphocytic activation molecule (SLAM)-associated protein (SAP), and X-linked inhibitor of apoptosis protein (XIAP) detections. Gene sequencing of family members of the patients were performed. Cytotoxicity and involved protein expression of some family members were detected.

Gene sequencing
Using specific-primer design and PCR on DNA extracted from mononuclear cells, the exon and related cleavage products of HLH-related genes were obtained. This was followed by bi-directional Sanger sequencing. The pathogenic variants and types were identified by Esembl genomic databases. To see if a pathogenic variant has been previously reported before, some information were identified by the Exome Aggregation Consortium (ExAC) and Human Gene Mutation Database (HGMD). The pathogenicity of single nucleotide polymorphisms was predicted by Polyphen2 and SIFT databases. Polyphen2 > 0.95 or SIFT < 0.05 predicted that the amino acid change caused by pathogenic variant may affect protein expression or function.

HSCT
Pre-transplant treatment was conducted based on an HLH-94/04 regimen (i.e., etoposide, glucocorticoid, and cyclosporine) and a DEP regimen (i.e., methylprednisolone, liposomal adriamycin, and etoposide). For donor selection of the HSCT, complete matching and gene screening of patients’ parents and siblings were conducted, followed by complete family surveys. NK cell activity and CD107a detections, as well as primary hemophagocytic gene screening, were performed in all donors to exclude the possibility of primary hemophagocytosis.
**Statistical methods**

SPSS version 22.0 was used for statistical analysis. All the data that conformed to the normal distribution was represented by x±SD and paired t test was used, while non-normal-distributed data was presented using the median and extreme values, Wilcoxon's rank-sum test was used. Statistical difference was defined as \( P < 0.05 \), significant statistical difference was defined as \( P < 0.01 \).

**Results**

**General conditions of adult patients with primary HLH**

Of the 18 adult HLH patients, there were 10 males (55.6%) and 8 females (44.4%), with the median age of onset at 25.5 years (18, 54). Of these 18 cases, pathogenic variants were found in the following genes: \( PRF1 \) (\( n = 11 \)), \( UNC13D \) (\( n = 5 \)), \( SH2D1A \) (\( n = 2 \)), \( RAB27a \) (\( n = 1 \)), and \( LYST \) (\( n = 2 \)). One patient had pathogenic variants in both \( PRF1 \) and \( UNC13D \) genes, one patient had pathogenic variants in both \( LYST \) and \( UNC13D \) genes and another patient had pathogenic variants in both \( PRF1 \) and \( SH2D1A \) genes. Three of the 18 cases involved homozygous pathogenic variants, while 2 cases involved hemizygous pathogenic variants. The remaining 13 cases involved compound heterozygous pathogenic variants. Pathogenic variants patterns included missense pathogenic variant, nonsense pathogenic variant, and frameshift pathogenic variant. Adult primary HLH gene pathogenic variants are listed in Table 1.

**Immunological marker and family surveys of adult patients with primary HLH**

**Detection of immunological markers**

Detection of immunological markers, including cytotoxicity, CD107a, perforin, granzyme, \( SAP \), and \( XIAP \) were performed in the 18 primary HLH patients (Table 2). The NK cell activity test was conducted in all 18 cases where 14 (77.8%) patients showed reduction in NK cell activity. The 8 patients who completed the CD107a degranulation assay, P08, P09, and P10 showed normal CD107a expression whereas P11, P12, P13, P14, and P17 showed reduced CD107a expression (In 6 patients with \( UNC13D \) or \( RAB27a \) or \( LYST \) pathogenic variants who also completed the CD107a degranulation assay, 5 patients have decreased CD107a expression, P10 showed normal CD107a expression). Among the 8 patients who completed the perforin assay, P03, P06, P08, and P09 had reduction of perforin levels, while P10, P11, P13, and P17 had normal perforin levels. (In 5 patients with \( PRF1 \) pathogenic variants who also completed the perforin assay, 4 patients have decreased perforin expression) No significant abnormality was noted among the 3 patients who completed the \( SAP \) and \( XIAP \) protein assays, and their gene detections showed no involvement of \( SH2D1A \) and \( XIAP \) gene.

**Family surveys of adult patients with primary HLH**

Among the 12 patients who underwent family surveys, some of their relatives completed gene sequencing and detection of immunological markers. This study was selected to further interpret the representative pedigree findings of 3 cases, including P11 (with \( UNCI13D \) homozygous missense pathogenic variant), P03 (with \( PRF1 \) compound heterozygous pathogenic variant), and P16 (with \( SH2D1A \) hemizygous missense pathogenic variant).

**Investigation of families of individuals with homozygous pathogenic variants**

Investigation of the family of P11 showed that: proband, male, 52 years old. \( UNC13D \) had a homozygous missense pathogenic variant at c.2588G > A. Family surveys of P11 were confirmed by Sanger sequencing, which showed that the patient's father and offspring also had heterozygous pathogenic variants. Patient's mother did not complete the family survey. However, given the homozygous pathogenic variant of P11, patient’s parents should have heterozygous pathogenic variant at the same locus. In addition, P11's sibling also had the same homozygous missense pathogenic variant but did not suffer from HLH. Cytotoxic degranulation (CD107a expression) of P11 and his sibling was reduced (Figs. 1 and 2).

**Investigation of families of individuals with compound heterozygous pathogenic variants**

Investigation of the family of P03 showed that: proband, male, 18 years old. \( PRF1 \) had compound heterozygous pathogenic variants, including a heterozygous missense pathogenic variant at c.172 T > C and a non-frameshift pathogenic variant at c.1083_1094del. Family surveys of P03 showed that P03 had suspected a positive family history of HLH, as two elder siblings of P03 died from unexplained fevers in their childhoods. Through Sanger sequencing, the two pathogenic variants of P03 originated from P03's parents. However, P03 also had two healthy siblings who carried different pathogenic variants (Figs. 3 and 4).

**Investigation of families of individuals with Hemizygous pathogenic variants**

Investigation of the family of P16 showed that: proband, male, 32 years old. \( SH2D1A \) had a hemizygous pathogenic variant at c.32 T > G, and the family surveys of P16 showed that P16's maternal grandfather died at 30+ years old with an unknown cause of death. P16's nephew (the offspring of P16's elder sibling, 1-year-old) simultaneously had the same onset with similar symptoms as P16 and died within a week after hospital admission. Through Sanger sequencing, the pathogenic variant of P16 originated from P16's mother, and three siblings of P16 also carried the same pathogenic variant, P16's mother and three siblings did
| Patient Number | Age at Diagnosis | Gender | Involved Gene | Site and Type of Pathogenic Variants | Change in Amino Acid | NM_ Polyphen2 (HDIV) | SIFT | ExAC_ALL | HGMD (Disease) |
|----------------|------------------|--------|---------------|-------------------------------------|----------------------|----------------------|-------|----------|----------------|
| P01            | 18               | F      | PRF1          | c.1168C > T (heterozygous nonsense pathogenic variant) | p. R390X             | NM_001083116 NM_005041 | –     | –        | Cytophagic histiocytic panniculitis |
|                |                  |        |               | c.1349C > T (heterozygous missense pathogenic variant) | p.T450 M             | 1                    | 0.001 | 0.00004957 | Haemophagocytic lymphohistiocytosis, familial |
| P02            | 19               | M      | PRF1          | c.1349C > T (homozygous missense pathogenic variant) | p.T450 M             | NM_001083116 NM_005041 | 1     | 0.001    | Haemophagocytic lymphohistiocytosis, familial |
| P03            | 18               | M      | PRF1          | c.172T > C (heterozygous missense pathogenic variant) | p.S58P               | NM_001083116 NM_005041 | 0.159 | 0.055    | –                |
|                |                  |        |               | c.1083_1094del (heterozygous nonframeshift pathogenic variant) | p.361_365del         | –                    | –     | –        | –                |
| P04            | 54               | F      | PRF1          | c.65delC (heterozygous frameshift pathogenic variant) | p. P22RfsX29         | NM_001083116 NM_005041 | –     | –        | Haemophagocytic lymphohistiocytosis, familial |
|                |                  |        |               | c.674G > A (heterozygous missense pathogenic variant) | p.R225Q              | 0.05                 | 0.366 | 0.001    | –                |
| P05            | 27               | M      | PRF1          | c.503G > A (heterozygous missense pathogenic variant) | p.S168 N             | NM_001083116 NM_005041 | 0.035 | 0.45     | Haemophagocytic lymphohistiocytosis, familial |
|                |                  |        |               | c.65delC (heterozygous missense pathogenic variant) | p.P22RfsX29          | –                    | –     | 0.001    | Haemophagocytic lymphohistiocytosis, familial |
| P06            | 18               | F      | PRF1          | c.1090_1091del (heterozygous frameshift pathogenic variant) | p.T364delX93         | NM_001083116 NM_005041 | –     | –        | Haemophagocytic lymphohistiocytosis, familial |
|                |                  |        |               | c.1349C > T (heterozygous missense pathogenic variant) | p.T450 M             | 1                    | 0.001 | 0.00004957 | Haemophagocytic lymphohistiocytosis, familial |
| P07            | 18               | M      | PRF1          | c.65delC (heterozygous frameshift pathogenic variant) | p. P22RfsX29         | NM_001083116 NM_005041 | –     | –        | Haemophagocytic lymphohistiocytosis, familial |
|                |                  |        |               | c.1349C > T (heterozygous missense pathogenic variant) | p.T450 M             | 1                    | 0.001 | 0.00004957 | Haemophagocytic lymphohistiocytosis, familial |
| P08            | 18               | F      | PRF1          | c.380A > G (heterozygous missense pathogenic variant) | p.N127S              | NM_001083116 NM_005041 | 0.999 | 0         | –                |
|                |                  |        |               | c.853_855delAAG (heterozygous frameshift pathogenic variant) | p.K285del            | –                    | –     | 0.00005766 | Haemophagocytic lymphohistiocytosis, familial |
| P09            | 18               | F      | PRF1          | c.46C > T (heterozygous missense pathogenic variant) | p.P165               | NM_001083116 NM_005041 | 0.995 | 0.19     | –                |
|                |                  |        |               | c.1066C > T (heterozygous missense pathogenic variant) | p.R356W              | 0.208                | 0.016 | 0.00008576 | Haemophagocytic lymphohistiocytosis, familial |
| P10            | 36               | M      | PRF1          | c.133G > A (heterozygous missense pathogenic variant) | p.G45R               | NM_001083116 NM_005041 | 1     | 0         | –                |
|                |                  |        |               | c.1228C > T (heterozygous missense pathogenic variant) | p.R410W              | 1                    | 0.009 | 0.00005111 | Haemophagocytic lymphohistiocytosis, familial |
| UNC1           |                  |        |               |                                | p.R427Q              | NM_199242             | 1     | 0.005    | –                |
| patient number | age at diagnosis | gender | involved gene | site and type of pathogenic variants | change in amino acid | NM_ | Polyphen2(HDM) | SIFT | ExAC_ALL | HGMD (Disease) |
|----------------|------------------|--------|---------------|-------------------------------------|----------------------|-----|--------------|------|----------|----------------|
| P11            | 52               | M      | UNC13D        | c.1280G > A (heterozygous missense pathogenic variant) | p.G863D              | NM_199242 | 1          | 0    | 0.0004   | Haemophagocytic lymphohistiocytosis, familial |
| P12            | 24               | F      | UNC13D        | c.2588G > A (homozygous missense pathogenic variant) | p.C136Y              | NM_199242 | 1          | 0    | –        | –              |
| P13            | 28               | M      | UNC13D        | c.407G > A (heterozygous missense pathogenic variant) | p.R214X              | –            | –          | 0.00000824 | Haemophagocytic lymphohistiocytosis, familial |
| P14            | 18               | M      | UNC13D        | c.3134C > T (heterozygous missense pathogenic variant) | p. T1045 M           | NM_199242 | 0.598      | 0.158 | 0        | –              |
| P15            | 27               | M      | PRF1          | c.11268-5 T > – (heterozygous missense pathogenic variant) | –                   | NM_000081 | –          | –    | –        | –              |
| P16            | 32               | M      | SH2D1A        | c.127C > A (heterozygous missense pathogenic variant) | p.A3S                | NM_00111497 | 0          | 0.84 | 0.0002   | Lymphoproliferative syndrome, X-linked |
| P17            | 34               | F      | RAB27a        | c.244C > T (homozygous missense pathogenic variant) | p.R82C              | NM_004580 | NM_183234 | 0.999 | 0.002    | –              |
| P18            | 32               | F      | LYST          | c.8368A > C (heterozygous missense pathogenic variant) | p.K2790Q            | NM_000081 | NM_001301365 | 0.38 | 0.021    | 0.0008        |
| Table 2 Immunological marker of adult patients with primary HLH |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| number          | NK number       | CD107a          | CD107a          | ΔPRF1           | ΔGranzymeB      | ΔSAP            | XLPAP           | classification  |
|                 | ≥15.11% normal  | (ΔCD107a) > 10% | (ΔMFI) ≥2.8 normal | NK ≥81% normal  | NK ≥77% normal  | NK (26–70) % normal | NK (59–100) % normal |                  |
| P01             | 18.68%          | –               | –               | –               | –               | –               | –               | FHL2            |
| P02             | 11.37%          | –               | –               | –               | –               | –               | –               | FHL2            |
| P03             | 10.74%          | –               | –               | NK 6.93% normal | NK 75% normal  | –               | –               | FHL2            |
| P04             | 1.74%           | –               | –               | –               | –               | –               | –               | FHL2            |
| P05             | 15.69%          | –               | –               | –               | –               | –               | –               | FHL2            |
| P06             | 9.9%            | –               | –               | NK 0.31% normal | –               | –               | –               | FHL2            |
| P07             | 10.6%           | –               | –               | –               | –               | –               | –               | FHL2            |
| P08             | 16.20%          | 20.05%          | 3.0%            | NK 78% normal  | NK 97% normal  | NK 62.1% normal | NK 66.03% normal | FHL2            |
| P09             | 11.29%          | 13.75%          | 3.0%            | NK 33% normal  | NK 99.87% normal | –               | –               | FHL2            |
| P10             | 9.86%           | 29.95%          | 3.7%            | NK 95.88% normal | NK 97.02% normal | NK 86.88% normal | NK 87.94% normal | FHL2            |
| P11             | 13.5%           | 10.76%          | 2.5%            | –               | –               | –               | –               | FHL3            |
| P12             | 12.27%          | 5.52%           | 1.5%            | NK 89.36% normal | NK 97.73% normal | –               | –               | FHL3            |
| P13             | 17.59%          | 9.18%           | 5.9%            | NK 85.1% normal | NK 71.52% normal | NK 65.92% normal | NK 95.52% normal | FHL3            |
| P14             | 11.14%          | 1.36%           | 0.86%           | –               | –               | –               | –               | –               |
| P15             | 15.3%           | –               | –               | –               | –               | –               | –               | XLP-1           |
| P16             | 11.08%          | –               | –               | –               | –               | –               | –               | XLP-1           |
| P17             | 5.4%            | 9.36%           | 2.2%            | NK 89.42% normal | NK 89.48% normal | –               | –               | GS-2            |
| P18             | 13.67%          | –               | –               | –               | –               | –               | –               | CH5             |

Fig. 1 Family diagram and gene sequencing of P11
not suffer from HLH. The expression of \textit{SH2D1A} gene encoded relevant protein \textit{SAP} of P16 was reduced (Figs. 5 and 6).

Allo-HSCT in adult patients with primary HLH

Table 3 shows the general information of the patients with follow-ups until May 2017. Among the 8 patients who received Allo-HSCT, one HLH patient died while the remaining seven HLH patients survived. Of the 10 patients who did not receive Allo-HSCT, 7 patients died, 1 was lost to follow-up, the other 2 patients survived. The 8 patients who underwent Allo-HSCT had a median survival of 27.2 months, as compared with the median survival of 7 months for the 10 patients who did not undergo Allo-HSCT, a significant difference between the two groups of patients ($p = 0.006$).
Discussion

Primary HLH is a rapidly progressive and life-threatening disease characterized by a reduction of NK cell and cytotoxic T lymphocyte function caused by genetic defects, resulting in excessive immune activation. Patients with an onset before 2 years of age account for more than 90% of all patients [3]. At least 12 relevant genes associated with primary HLH have been reported, changes in gene sequences were reported in adult HLH patients in the subsequent studies. Delayed onset of adult primary HLH has been considered to relate to the gene pathogenic variants, the pathogenic variant patterns, and the presence of a trigger. For example, a study by Ueda et al. [11] analyzed the gene pathogenic variants in pediatric HLH patients and showed that nonsense and frameshift pathogenic variants that occurred in infants mostly happened in the classical onset of HLH while missense pathogenic variants occurred in the later onset of the disease at older ages. Pagel et al. [12] found that patients with STXBP2 splice-site pathogenic variants, as compared with patients carrying nonsense pathogenic variants, had a higher age of onset with a median age of 4.1 years and 2 months, respectively. The age of onset of compound heterozygous pathogenic variants involved only the perforin or the degranulation pathway was later than the age of onset of the homozygous pathogenic variants [9]. The presence of a trigger also plays an important role in the incidence of primary HLH. For example, A91V is a milder class I perforin mutation with partial maturation and reduced but
detectable perforin and NK function [13]. A91V confers genetic susceptibility for the development of FHL, but is not enough to trigger the disease on its own, the M. tuberculosis infection as synergistic factors play a role in the development of FHL [14]. In our data, in the family surveys of P11, the sibling of the proband P11 had the same homozygous pathogenic variant as P11. In addition, the cytotoxic degranulation (CD107a expression) was reduced in P11’s sibling but with no incidence of HLH. The plausible reason was that P11 had positive EBV-DNA(8.2 × 10^5 copies/ml) while P11’s sibling had negative EBV-DNA. In the family surveys of P16, the proband had positive EBV-DNA(8.8 × 10^4 copies/ml) detected when he suffered from HLH in 32 years old, P16’s maternal grandfather and nephew died with an unknown cause, we speculate that the possibility of the occurrence of HLH can not be excluded. P16’s mother and three siblings had no evidence of EBV infection or other triggering factor(s), although they carried the same pathogenic variant, they did not suffer from HLH. This would suggest that in addition to inherent immune deficiency, other triggering factor(s) might be involved in the incidence of primary HLH. Age was no longer the diagnostic basis of primary HLH. Our data also showed that approximately 72% of the 18 adult patients with primary HLH had compound heterozygous pathogenic variants. Some of the pathogenic variants (such as c.1349C > T) were reported before in other patients with late onset

![Fig. 6](representative_imageShowing_the_SAP_protein_expression.png)

Table 3 The general information of adult patients with primary HLH who received Allo-HSCT

| Patient’s number | P02 | P03 | P08 | P11 | P12 | P14 | P15 | P17 |
|------------------|-----|-----|-----|-----|-----|-----|-----|-----|
| Donor origin     | PB  | PB  | PB  | PB  | PB  | PB  | PB  | PB  |
| HLA typing       | 5/10| 5/10| 5/10| 5/10| 5/10| 5/10| 5/10| 5/10|
| Stem cell type   | PB  | PB  | PB  | PB  | PB  | PB  | PB  | PB  |
| Pretreatment regimens | TBI/VP16/CTX | TBI/VP16/Cy | TBI/VP16/Cy | TBI/VP16/Cy | VP16/Bu/Cy | VP16/Bu/FLU/ATG | TBI/VP16/CTX | VP16/Bu/FLU/ATG |
| White blood cell viability (days) | +10 | +11 | +8  | +12 | +13 | +10 | +18 | +15 |
| Platelet engraftment time (days)   | +13 | +12 | +10 | +13 | +13 | +15 | +18 | +15 |
| +20d donor chimerism rate     | 100%| 99.6%| 100%| 100%| 99.04%| 100%| 100%| 97.78%|
| GVHD               | III | –   | –   | I   | –   | –   | –   | –   |
| Pre-transplant EBV copy   | 0   | 0   | 5.1×10^4 | 8.2×10^5 | 0   | 1.5×10^4 | 9.2×10^3 | 0   |
| Post-transplant EBV copy  | 0   | 0   | 0   | 0   | 0   | 0   | 0   | 0   |
| Prognosis           | survival | survival | survival | death | survival | survival | survival | survival |
HLH [11], which also partly explained the reason for the HLH onset in adulthood.

Janka et al. [3] showed that NK cell activity was reduced in almost all patients at the early stage of primary HLH. Our result showed that the NK cell activity test was conducted in all 18 cases where 14 (77.8%) patients showed reduction in NK cell activity. Thus, timely detection of NK cell activity is important for the early diagnosis of the disease. In this study, 4 primary HLH patients had normal NK cell activity, indicating that normal NK cell activity could not completely exclude the possibility of primary HLH as a diagnosis. Rapid immunological assays such as CD107a expression could be used to verify the HLH diagnosis and provide the etiology data that quickly divides HLH into two categories. Genetic defects, which affected the cytotoxic degranulation routes, led to the functional impairment of the transfer of lysosomal-related membrane glycoprotein CD107a to the cell surface, thereby significantly reducing the CD107a expression. NK degranulation analyses clearly distinguished the patients with granule exocytosis dysfunction, secondary HLH, or other hereditary defects such as SAP and XIAP deficiencies. A previous study has shown that patients with secondary HLH and other types of primary HLH have normal CD107a expression [4]. In this study, of the 8 patients who completed the CD107a detection, 3 of them showed normal CD107a expression. Five of the 8 patients had reduced CD107a expression, with UNC13D and RAB27a genes affected, which influenced the degranulation function. P10 with single heterozygous nonsense pathogenic variant of UNC13D showed normal CD107a expression, the reason may that the single heterozygous nonsense pathogenic variant of UNC13D was not enough to cause CD107a expression reduction. No significant abnormality was noted among the 3 patients who completed the SAP and XIAP protein assays, and their gene detections showed no involvement of SH2D1A and XIAP gene. These findings suggest that immunological marker detections and genetic testing results match each other well. However, in terms of timeliness, the detection of immunological markers was significantly superior to the genetic testing. Therefore, immunological markers played an important role in the early diagnosis of primary HLH.

Active HLH disease progresses rapidly, and without timely and effective treatment, the median survival time is only 2 months [15]. Allo-HSCT is the only curative regimen for primary HLH. Current reports in adult primary HLH treatment using Allo-HSCT are limited. Among the 8 adult primary HLH patients who received Allo-HSCT in this study, their chimerism after transplantation was complete. The 4 EBV-positive patients (P08, P11, P14, P15) in this study became EBV-negative after the Allo-HSCT, indicating that Allo-HSCT corrected the immunodeficiency and allowed the patients to have the ability to clear EBV. The median survival time of the Allo-HSCT group was 27.2 months, which was significantly higher than the non-Allo-HSCT group (p = 0.006). Allo-HSCT was an effective therapy for adult primary HLH.
Conclusions
Untreated primary HLH patients have a very low survival rate. Family surveys and immunological markers were important for the HLH diagnosis and the selection of an appropriate donor. Allo-HSCT was an effective therapy for adult primary HLH. To date, the diagnostic and treatment data of adult primary HLH patients have been rarely reported. Therefore, we should better review existing cases, to identify the suitable timing to apply Allo-HSCT, select the appropriate transplant donor, and develop a more unified transplantation program to improve the treatment efficacy.

Abbreviations
Allo-HSCT: Allogeneic hematopoietic stem cell transplantation; ATG: Antithymocyte globulin; BU: Busulfan; CY: Cyclo-phosphamide; ExAC: Exome Aggregation Consortium; FLU: Fludarabine; HGMD: Human Gene Mutation Database; HLH: Hemophagocytic lymphohistiocytosis; MAC: Myeloablative stem cell transplantation; NK: Natural Killer;RIC: Reduced-intensity conditioning; SAP: SLAM-associated protein; SLAM: Signaling lymphocytic activation molecule; TBI: Total body irradiation; VOD: Veno-occlusive disease; XAP: X-linked inhibitor of apoptosis protein

Acknowledgements
Not applicable.

Funding
This work was supported by the National Natural Science Foundation of China under Grant number 81401627; Natural Science Foundation of Beijing Municipality under Grant number 69020078; and Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding(ZYLX201702).

Availability of data and materials
Please contact author for data requests.

Authors’ contributions
JZ collected and analyzed data, and drafted the manuscript. YW, JW, JZ, LW, ZH, ZG, WL, ZW participated in the design of the study and performed the statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable, our study was analyzed retrospectively and it conforms to the provisions of the Declaration of Helsinki.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 16 July 2017 Accepted: 29 December 2017
Published online: 22 January 2018

References
1. Stepp SE, Dufourcq-Lagelouze R, Le DF, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis[J]. Science. 1999;286(5446):1857–9.
2. Chandrakasan S, Filippovich AH. Hemophagocytic lymphohistiocytosis: advances in pathophysiology, diagnosis, and treatment[J]. J Pediatr. 2013;163(5):1253–9.
3. Janka GE. Familial and acquired hemophagocytic lymphohistiocytosis[J]. Eur J Pediatr. 2007;166(2):95–109.
4. Bryceson YT, Pende D, Mau-Pavicic A, et al. A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes. Blood. 2012;119(12):2754–63.
5. Jordan MB, Allen CE, Weitman S, et al. How I treat hemophagocytic lymphohistiocytosis[J]. Blood. 2011;118(15):4041–52.
6. Trottestam H, Horne A, Arico M, et al. Chemoinmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011;118:4577–84.
7. Henter J, Horne AC, Arico M, et al. HHV-2004 diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer. 2007;48(1):124–31.
8. Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunchemotherapy and bone marrow transplantation. Blood. 2002;100:2367–73.
9. Zhang K, Chandrakasan S, Filippovich AH, et al. Synergistic defects of different molecules in the cytokinetic pathway lead to clinical familial hemophagocytic lymphohistiocytosis. Blood. 2014;124(8):1331–4.
10. Sepulveda FE, Garigue A, Maschaldi S, et al. Polygenic mutations in the cytotoxicity pathway increase susceptibility to develop HLH immunopathology in mice. Blood. 2016;127(17):2113–21.
11. Ueda I, Ishii E, Morimoto A, et al. Correlation between phenotypic heterogeneity and gene mutational characteristics in familial hemophagocytic lymphohistiocytosis (FHL). Pediatr Blood Cancer. 2006;46(4):482–8.
12. Pagel J, Beulet L, Lehmkberg K, et al. Distinct mutations in STXB2 are associated with variable clinical presentations inpatients with familial hemophagocytic lymphohistiocytosis type 5 (FHL5). Blood. 2012;119(26):6016–24.
13. Risma KA, Frayer RW, Filippovich AH, Sumegi J. aberrant maturation of mutant perforin underlies the clinical diversity of hemophagocytic lymphohistiocytosis. J Clin Invest. 2006;116:139–22.
14. Maneiro E, Allende LM, Guzmán M, et al. Familial hemophagocytic lymphohistiocytosis in an adult patient homozygous for A91V in the perforin gene, with tuberculosis infection. Haematologica. 2006;91(9):1257–60.
15. Janka GE. Familial hemophagocytic lymphohistiocytosis. Eur J Pediatr. 1983;140(3):221–30.
16. Marsh RA, Vaughn G, Kim MD, et al. Reduced-intensity conditioning significantly improves survival of patients with hematophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation. Blood. 2010;116(26):5824–31.
17. Ouachee-Chardin M, Elie C, de Saint BG, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: asingle-center report of 48 patients. Pediatrics. 2006;117(4):743–50.
18. Jordan MB, Filippovich AH. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant. 2008;42(7):433–7.
19. Baker KS, Filippovich AH, Gross TG, et al. Unrelated donor hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis. Bone Marrow Transplant. 2008;42(3):175–80.
20. Amayiri N, Al-Zaben A, Ghatasheh L, et al. Hematopoietic stem cell transplantation for children with primary immunodeficiency diseases: single center experience in Jordan. Pediatr Transplant. 2013;17:394–402.

Submit your next manuscript to BioMed Central and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit